BASEL, Switzerland,
June 8, 2017 /PRNewswire/ --
Ascensia Diabetes Care today announced
it has entered into a strategic alliance by signing a development
agreement with Insulet Corporation (NASDAQ: PODD), the leader in
tubeless insulin pump technology with its Omnipod®
Insulin Management System (the Omnipod System). Under the terms of
this agreement, the Ascensia CONTOUR®NEXT ONE blood
glucose monitoring system (BGMS) will connect to Insulet's
next-generation Omnipod System (the Omnipod Dash™ System), which is
currently in development. Seamlessly connecting the
CONTOUR®NEXT ONE BGMS and the Omnipod Dash™ System will
provide people living with diabetes with an innovative continuous
insulin delivery system to manage their diabetes, powered by
remarkably accurate blood glucose readings.
The CONTOUR®NEXT ONE BGMS will pair, via Bluetooth
Low Energy (BLE), with the Omnipod Dash™ Personal Diabetes Manager
(Omnipod Dash™ PDM) to automatically transmit a person's blood
glucose readings directly into the system. These readings will be
used by the Omnipod Dash™ PDM to calculate insulin dosing and
support highly accurate delivery of insulin for people living with
diabetes. Under the terms of this worldwide non-exclusive
agreement, Insulet will develop and seek marketing clearance for
the Omnipod Dash™ PDM, with collaboration from Ascensia Diabetes
Care who will provide the CONTOUR®NEXT ONE meter and
CONTOUR®NEXT test strips.
"We are delighted to enter into this agreement that brings
together these innovative technologies from both companies," said
Michael Kloss, CEO, Ascensia
Diabetes Care. "The integration of our BGM system with Insulet's
tubeless insulin pump system has significant potential to help
people take control of their lives and their diabetes. We are
pleased that our highly accurate system has been chosen to provide
the critical blood glucose data that will be used by the Omnipod
Dash™ PDM to calculate insulin dosing for patients."
“We are thrilled to partner with Ascensia as part of our
development efforts on our next-generation Omnipod Dash platform,
which will allow Insulet to maintain its competitive edge with
truly innovative and differentiated products,” said Shacey Petrovic, President and Chief Operating
Officer.
The CONTOUR®NEXT ONE BGMS received 510(k) clearance
from the FDA in November 2016 and has
been shown to meet the stricter accuracy requirements of the FDA
Over-the-Counter BGMS Guidance that was recently issued in 2016. In
a clinical study, 95% of blood glucose results obtained with the
CONTOUR®NEXT ONE BGMS were within 8.4 mg/dL (0.5 mmol/L)
or 8.4% of the reference result for subject fingertip
tests.[1]
Michael added, "This alliance is the next step in our goal of
providing integrated solutions for people living with diabetes. We
believe that integrated diabetes management is the future and are
happy to work with partners that will help us to achieve this goal
together. One aspect of this is pump therapy, where we have
established ourselves as the partner of choice for blood glucose
monitoring in the pump sector. We are excited that Insulet
recognizes the value the CONTOUR®NEXT ONE BGMS can bring
to users of Omnipod's product platform."
Notes for Editors
About Ascensia Diabetes Care
Ascensia Diabetes Care is a global specialist diabetes care
company, dedicated to helping people living with diabetes. Our
mission is to empower people living with diabetes through
innovative solutions that simplify and improve their lives. We use
our innovation and specialist expertise in diabetes to develop high
quality solutions and tools that make a positive, daily difference
for people with diabetes.
Home to the world renowned CONTOUR® portfolio of
blood glucose monitoring systems, our products combine advanced
technology with user-friendly functionality that help people with
diabetes to manage their condition. We are committed to continued
research, innovation and development of new products and solutions.
As a trusted partner in the diabetes community, we collaborate
closely with healthcare professionals and other partners to ensure
our products meet the highest standards of accuracy, precision and
reliability, and that we conduct our business compliantly and with
integrity.
Ascensia Diabetes Care was established in 2016 through the sale
of Bayer Diabetes Care to Panasonic Healthcare Holdings Co., Ltd.
Ascensia Diabetes Care products are sold in more than 125
countries. Ascensia Diabetes Care has around 1,700 employees and
operations in 33 countries.
For further information, please visit the Ascensia Diabetes Care
website at: http://www.ascensia.com.
About Insulet Corporation
Insulet Corporation (NASDAQ: PODD) is an innovative medical
device company dedicated to making the lives of people with
diabetes easier. Through its Omnipod Insulin Management System,
Insulet seeks to expand the use of insulin pump therapy among
people with insulin-dependent diabetes. The Omnipod is a
revolutionary and easy-to-use tubeless insulin pump that provides
up to three days of non-stop insulin delivery, without the need to
see or handle a needle. Insulet's Delivery Systems business
also partners with global pharmaceutical and biotechnology
companies to adapt the Omnipod technology platform for the delivery
of subcutaneous drugs across multiple therapeutic areas. Founded in
2000, Insulet Corporation is based in Billerica, Massachusetts. For more
information, please visit: http://www.myomnipod.com.
© 2017 Ascensia Diabetes Care. Ascensia and Contour are
trademarks and/or registered trademarks of Ascensia Diabetes Care.
All other trademarks are the property of their respective owners.
The use of third party trademarks does not constitute an
endorsement or imply a relationship or other affiliation.
References
1. Christiansen et al. Poster presented at the 15th Annual
Meeting of the Diabetes Technology Society, October 22-24, 2015, Bethesda, Maryland.
For further information, please contact:
Joseph Delahunty
Ascensia Diabetes Care
joseph.delahunty@ascensia.com
Tel: +41-61-560-8760